{"id":6530,"date":"2018-12-17T17:01:53","date_gmt":"2018-12-17T09:01:53","guid":{"rendered":"https:\/\/nhri.raise-up.com.tw\/dbpr211\/"},"modified":"2021-09-02T17:52:47","modified_gmt":"2021-09-02T09:52:47","slug":"dbpr211","status":"publish","type":"post","link":"https:\/\/ttic.nhri.edu.tw\/en\/dbpr211\/","title":{"rendered":"Technology Available for Industry-Academia Collaboration or Technology Licensing. \u201cDBPR211: a peripheral CB1 receptor antagonist\u201d\uff082018\/12\/17\uff09"},"content":{"rendered":"\r\n<h4 class=\"wp-block-heading\">Title:<\/h4>\r\n\r\n\r\n\r\n<p>NHRI technology, \u201cDBPR211: a peripheral CB1 receptor antagonist\u201d (abbreviated as \u201cThe Technology\u201d) available for industry-academia collaboration or technology licensing.<\/p>\r\n\r\n\r\n\r\n<h4 class=\"wp-block-heading\">Description:<\/h4>\r\n\r\n\r\n\r\n<p>Cannabinoid receptor 1 (CB1) is expressed in several peripheral tissues related to metabolic control and its dysregulation contributes to metabolic disorders. DBPR211 is a highly selective antagonist of peripheral CB1 receptors. It exhibits beneficial effects in treating insulin resistance\u200b, obesity and non-alcoholic fatty liver disease. This unique mechanism may potentially render DBPR211 as a highly competitive first-in-class drug candidate for the treatment of type 2 diabetes, obesity and non-alcoholic fatty liver disease.<\/p>\r\n\r\n\r\n\r\n<h4 class=\"wp-block-heading\">Potential collaboration partner qualifications:<\/h4>\r\n\r\n\r\n\r\n<ol>\r\n<li>be incorporated and approved by law and does not have any record of misconduct or conviction for any offense<\/li>\r\n<li>better to have related experience and skills for developing The Technology<\/li>\r\n<li>better to have experience of international collaboration and clinical trial<\/li>\r\n<li>be willing to provide long-term investment<\/li>\r\n<\/ol>\r\n\r\n\r\n\r\n<h4 class=\"wp-block-heading\">Registration\uff1a<\/h4>\r\n\r\n\r\n\r\n<p>Please contact to Mr. Hua-Hsuan Liang (Address: Technology Transfer and Incubation Center, National Health Research Institutes, 35 Keyan Road, Zhunan Town, Miaoli County 35053, Taiwan, R.O.C., Tel: +88637-246166#33206, E-mail: huahsuan@nhri.org.tw).<\/p>\r\n\r\n\r\n\r\n<h4 class=\"wp-block-heading\">Other:<\/h4>\r\n\r\n\r\n\r\n<p>If The Technology has been exclusively licensed, this announcement will automatically invalid. For detailed status of The Technology, please contact to the case officer.<\/p>\r\n\r\n\r\n\r\n<p>Attachments:<\/p>\r\n\r\n\r\n\r\n<p>I:\u00a0<a href=\"http:\/\/www.nhri.org.tw\/NHRI_ADM\/userfiles\/file\/att1-DBPR211-EN-20190314.pdf\">Announcement<\/a><\/p>\r\n\r\n\r\n\r\n<p>II:\u00a0<a href=\"https:\/\/ttic.nhri.edu.tw\/wp-content\/uploads\/2019\/09\/att2_DBPR211_Licensing_-Proposal_EN-20190314.doc\" target=\"_blank\" rel=\"noreferrer noopener\" aria-label=\"Licensing Proposal (\u5728\u65b0\u5206\u9801\u4e2d\u958b\u555f)\">Licensing Proposal<\/a><\/p>\r\n\r\n\r\n\r\n<p>III:\u00a0<a href=\"http:\/\/www.nhri.org.tw\/NHRI_ADM\/userfiles\/file\/att3_DBPR211_collaboration_proposal-20190314.doc\">Industry-Academia Collaboration Proposal<\/a><\/p>\r\n","protected":false},"excerpt":{"rendered":"<p>Title: NHRI technology, \u201cDBPR211: a peripheral CB1 receptor antagonist\u201d (abbreviated as \u201cThe Technology\u201d) available for industry-academia collaboration or technology licensing. Description: Cannabinoid receptor 1 (CB1) is expressed in several peripheral tissues related to metabolic control and its dysregulation contributes to metabolic disorders. DBPR211 is a highly selective antagonist of peripheral CB1 receptors. It exhibits beneficial &hellip;<\/p>\n<p class=\"read-more\"> <a class=\"\" href=\"https:\/\/ttic.nhri.edu.tw\/en\/dbpr211\/\"> <span class=\"screen-reader-text\">Technology Available for Industry-Academia Collaboration or Technology Licensing. \u201cDBPR211: a peripheral CB1 receptor antagonist\u201d\uff082018\/12\/17\uff09<\/span> Read More &raquo;<\/a><\/p>\n","protected":false},"author":5,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[135,136,144],"tags":[],"table_tags":[],"acf":[],"_links":{"self":[{"href":"https:\/\/ttic.nhri.edu.tw\/en\/wp-json\/wp\/v2\/posts\/6530"}],"collection":[{"href":"https:\/\/ttic.nhri.edu.tw\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ttic.nhri.edu.tw\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ttic.nhri.edu.tw\/en\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/ttic.nhri.edu.tw\/en\/wp-json\/wp\/v2\/comments?post=6530"}],"version-history":[{"count":2,"href":"https:\/\/ttic.nhri.edu.tw\/en\/wp-json\/wp\/v2\/posts\/6530\/revisions"}],"predecessor-version":[{"id":7099,"href":"https:\/\/ttic.nhri.edu.tw\/en\/wp-json\/wp\/v2\/posts\/6530\/revisions\/7099"}],"wp:attachment":[{"href":"https:\/\/ttic.nhri.edu.tw\/en\/wp-json\/wp\/v2\/media?parent=6530"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ttic.nhri.edu.tw\/en\/wp-json\/wp\/v2\/categories?post=6530"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ttic.nhri.edu.tw\/en\/wp-json\/wp\/v2\/tags?post=6530"},{"taxonomy":"table_tags","embeddable":true,"href":"https:\/\/ttic.nhri.edu.tw\/en\/wp-json\/wp\/v2\/table_tags?post=6530"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}